Currently Closed – We are no longer accepting or processing applications for new or renewal patients.
The PAN Foundation’s Myelodysplastic Syndromes fund is currently closed. As of September 18, 2019, Patient Advocate Foundation is accepting applications.
For current information, log in to FundFinder.
$5,000 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.
- The patient must be getting treatment for myelodysplastic syndromes.
- The patient must have health insurance that covers his or her qualifying medication or product.
- The patient’s medication or product must be listed on PAN’s list of covered medications.
- The patient’s income must fall at or below 500% of the Federal Poverty Level.
- The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)
See the list of medications covered in this program
- Atgam (lymphocyte immune globulin,antithymocyte (equine))
- Azacitidine (azacitidine)
- Cyclosporine (cyclosporine)
- Cyclosporine Modified (cyclosporine, modified)
- Dacogen (decitabine)
- Decitabine (decitabine)
- Deferoxamine Mesylate (deferoxamine mesylate)
- Desferal (deferoxamine mesylate)
- Exjade (deferasirox)
- Gengraf (cyclosporine, modified)
- Gleevec (imatinib mesylate)
- Granix (tbo-filgrastim)
- Imatinib Mesylate (imatinib mesylate)
- Jadenu (deferasirox)
- Jakafi (ruxolitinib phosphate)
- Leukine (sargramostim)
- Methotrexate (methotrexate sodium)
- Neoral (cyclosporine, modified)
- Neupogen (filgrastim)
- Revlimid (lenalidomide)
- Sandimmune (cyclosporine)
- Vidaza (azacitidine)
- Zarxio (filgrastim-sndz)
ICD-10: C93.10, C93.11, C93.12, D46.0, D46.1, D46.20, D46.21, D46.22, D46.4, D46.9, D46.A, D46.B, D46.C, D46.Z
About the Disease:
Myelodysplastic Syndrome (MDS), also known as preleukemia, is a cancer caused by poorly formed or dysfunctional blood cells. MDS affects the nervous and immune systems.
Source: National Institutes of Health